Ajantha Abey narrates his blog written for Dementia Researcher.
In this blog, Ajantha discusses a renewed sense of optimism in Alzheimer's research, marked by the FDA approval of three new drugs in the last three years. These drugs represent a paradigm shift as they aim to modify the disease itself rather than just alleviate symptoms. Alongside these therapeutic advances, the field is benefiting from an expanded understanding of disease mechanisms and increasing industry investment, signalling meaningful progress and hope for future breakthroughs. Let's raise awarness for World Alzheimer's Day 2023.
Find the original text, and narration here on our website.
--
Ajantha Abey is a PhD student in the Kavli Institute at University of Oxford. He is interested in the cellular mechanisms of Alzheimer's, Parkinson's, and other diseases of the ageing brain. Previously, having previoulsy explored neuropathology in dogs with dementia and potential stem cell replacement therapies. He now uses induced pluripotent stem cell derived neurons to try and model selective neuronal vulnerability: the phenomenon where some cells die but others remain resilient to neurodegenerative diseases.
--
Enjoy listening and reading our blogs? We're always on the look out for new contributors, drop us a line and share your own research and careers advice dementiaresearcher@ucl.ac.uk
This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.